
TABLE OF CONTENTS

Dedication-----	ii-iv
Statement of authentication-----	v
Publications and abstracts-----	vi
Acknowledgements-----	vii-x
Abstract-----	xi-xii
List of Abbreviations-----	xiii-xvii
Table of contents-----	xviii-xxiv
Appendix-----	xxv
List of Figures-----	xxv-xxix
List of Tables-----	xxix-xxxi

CHAPTER 1

Literature Review

1	Literature Review -----	1
1.1	Introduction -----	2
1.1.1	Introduction to endometriosis-----	2-4
1.2	The normal endometrium -----	4
1.2.1	The female uterus-----	4-5
1.2.2	Endometrial changes during the menstrual cycle-----	5-10
1.3	Human endometriosis -----	11
1.3.1	Definition of endometriosis-----	11
1.3.2	The origin of endometriosis-----	12-13
1.3.3	The cause of endometriosis-----	13-16
1.3.4	Diagnosing endometriosis-----	17-19
1.3.5	Current therapies-----	19-22
1.3.6	Surgical treatments of endometriosis-----	22-23
1.4	The baboon animal model (<i>Papio anubis</i>) -----	23
1.4.1	Endometriosis and the baboon-----	23-24
1.4.2	Baboon histology-----	24-26
1.4.3	Inducing endometriosis in the baboon-----	26
1.5	Ubiquitin and the proteasome -----	26
1.5.1	Ubiquitin structure and function-----	26-30
1.5.2	Ubiquitin-proteasome pathway-----	30-31
1.5.3	Proteasome structure and function-----	31-34
1.6	The ubiquitin pathway and endometriosis -----	34
1.6.1	Why look at the ubiquitin system in endometriosis?-----	34-35
1.7	Apoptosis -----	35
1.7.1	History and detection-----	35-36
1.7.2	Apoptosis in the normal endometrium-----	36-37
1.7.3	Apoptosis in endometriosis-----	37-38

1.8	Proteins the Ubiquitin-NFκβ pathway-----	39
1.8.1	NFκβ structure and function-----	39-46
1.8.2	IKK structure and function-----	46-47
1.8.3	TNF-α structure and function-----	48-51
1.9	Aims of the study-----	51-53

CHAPTER 2

Materials and Methods

2	Immunohistochemistry-----	54
2.1	Baboons-----	55
2.1.1	Baboon tissues-----	55-56
2.1.2	Sectioning of baboon tissues-----	56
2.1.3	Immunohistochemistry of baboon tissues-----	56-57
2.1.4	Immunohistochemical grading of stained baboon tissues----	57-58
2.1.5	Statistical analysis of baboon tissues for immunohistochemistry-- -----	58-59
2.2	Humans-----	59
2.2.1	Human tissues-----	59
2.2.2	Sectioning of human tissues-----	59
2.2.3	Immunohistochemistry of human tissues-----	59-60
2.2.4	Immunohistochemical grading of stained human tissues-----	61
2.2.5	Statistical analysis of human tissues for immunohistochemistry-- -----	61
2.3	Quantitative real time polymerase chain reaction (qRT-PCR)-----	62
2.3.1	Baboon tissue collection for RT-PCR-----	62
2.3.2	Human tissue collection for RT-PCR-----	62-63
2.3.3	Human tissue RNA extraction-----	63-65
2.3.4	Measuring RNA quality and quantity in baboons and humans----- -----	65-67

2.3.5	Amplification of cDNA sequencing for baboons and humans-----	67-68
2.3.6	Designing primers and their validation for baboons and humans--	68-69
2.3.7	Real-time PCR for baboons and humans-----	69-70
2.3.8	Statistics for qRT-PCR for baboons and humans-----	70

CHAPTER 3

Molecular studies of human endometrial tissues

3	Quantitative real time polymerase chain reaction (qRT-PCR) in human endometrial tissues-----	75
3.1	Introduction-----	75
3.2	Materials and methods-----	75
3.2.1	Human tissues for qRT-PCR-----	75-76
3.3	Results-----	76-80
3.4	Discussion-----	80-81

CHAPTER 4

Molecular studies of baboon endometrial tissues

4	Quantitative real time polymerase chain reaction (qRT-PCR) in baboon endometrial tissues-----	83
4.1	Introduction-----	83
4.2	Materials and methods-----	83
4.2.1	Baboon tissues for qRT-PCR-----	83-84
4.3	Results-----	84-86
4.4	Discussion-----	86

CHAPTER 5

Immunohistochemical study of eutopic baboon endometrial tissues

5 Immunohistochemistry of eutopic baboon endometrial tissues -----	88
5.1 Introduction -----	88
5.1.1 Materials and methods -----	88
5.2.1 Animals-----	88
5.2.2 Immunohistochemistry-----	88
5.2.3 Immunohistochemistry grading of stained cells-----	88
5.2.4 Statistical analysis-----	89
5.2 Results -----	89
5.3.1 IKK β , I κ B α and NF κ B Immunostaining-----	89-93
5.3.2 Ubiquitin Immunostaining-----	93-95
5.3.3 TNF- α Immunostaining-----	95
5.3.4 Proteasome Immunostaining-----	95-98
5.3.5 IKK- α Immunostaining-----	98-99
5.3 Discussion -----	100-101

CHAPTER 6

Immunohistochemical study of ectopic baboon endometrial tissues

6 Immunohistochemistry of ectopic baboon endometrial tissues -----	103
6.1 Introduction -----	103
6.2 Materials and methods -----	103
6.2.1 Animals-----	103
6.2.2 Immunohistochemistry-----	103
6.2.3 Immunohistochemistry grading of stained cells-----	103

6.2.4	Statistical analysis-----	104
6.3	Results-----	104
6.3.1	Ubiquitin, TNF- α , IKK β , NF κ β Immunostaining-----	104-109
6.3.2	Proteasome Immunostaining-----	110-112
6.3.3	I κ β α Immunostaining-----	112
6.3.4	IKK- α Immunostaining-----	112-114
6.4	Discussion-----	115-117

CHAPTER 7

Immunohistochemical study of eutopic human endometrial tissues

7	Immunohistochemistry of eutopic human endometrial tissues-----	119
7.1	Introduction-----	119
7.2	Materials and methods-----	120
7.2.1	Human tissues-----	120
7.2.2	Immunohistochemistry-----	120
7.2.3	Immunohistochemistry grading of stained cells-----	120
7.2.4	Statistical analysis -----	120
7.3	Results-----	121
7.3.1	IKK β , I κ β α , NF κ β and IKK α Immunostaining-----	121-126
7.3.2	Proteasome Immunostaining-----	127
7.4	Discussion-----	127-129

CHAPTER 8

Immunohistochemical study of ectopic human endometrial tissues

8	Immunohistochemistry of ectopic human endometrial tissues-----	131
----------	---	------------

8.1 Introduction -----	131
8.2 Materials and methods -----	131
8.2.1 Human tissues-----	131-132
8.2.2 Immunohistochemistry-----	132
8.2.3 Immunohistochemistry grading of stained cells-----	132
8.2.4 Statistical analysis-----	133
8.3 Results -----	133
8.3.1 IKK β , NF κ β , 19S proteasome, I κ β α and IKK α immunostaining in proliferative phase-----	133
8.3.2 IKK β , NF κ β , 19S proteasome, I κ β α and IKK α immunostaining in secretory phase-----	133-148
8.4 Discussion -----	149

CHAPTER 9

General Discussion

9 General Discussion -----	150-154
-----------------------------------	----------------

CHAPTER 10

References

10 References -----	155-178
----------------------------	----------------

APPENDIX

Appendix 1.1: Drug treatment and procedures for endometriosis-----	180-181
---	----------------

Appendix 1.2: American Society of Reproductive Medicine, revised classification of endometriosis-----	182
---	------------

Appendix 1.3: IKK α . Conserved helix-loop-helix ubiquitous kinase (CHUK), mRNA-----183

Appendix 1.4: PA28. Homo sapien proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) (PSME1), transcript variant 1, mRNA-----184

Appendix 1.5: NF κ B subunit, p65.Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65 (avian) (RELA) mRNA-----185

LIST OF FIGURES

Figure 1.1: The human menstrual cycle. (A) Changes in pituitary gland hormones; (B) oocyte development with changes in hormone levels; (C) changes in ovarian hormone levels and (D) changes in endometrial cell thickness----- 9

Figure 1.2: A schematic view of the endometrial changes in the baboon (*Papio anubis*) and women during the menstrual cycle----- 10

Figure 1.3. Diagram illustrating treatment groups and sampling time points for the baboon. The days indicated below the lines are the times at which tissue was obtained. M = menses; EF = early follicular; LF = late follicular; ML = mid-luteal; LL = late luteal (Christensen *et al*, 1995)----- 25

Figure 1.4: The ubiquitin-proteasome mediated pathway. (Coux). “Regulation of the ubiquitin-proteasome system.” [Online] Available: <http://www.crblm.cnrs.fr/~coux/Eng3.html> [Accessed July. 1, 2008]----- 31

Figure 1.5: Schematic view of the 26S proteasome, which is made up of two outer 19S subunits that recognize polyubiquitinated target proteins and the inner catalytic 20S subunit that allows protein degradation (Adams 2004)-----33

Figure 1.6: Schematic view of the inter-relationships between the proteins in the ubiquitin-NF κ B pathway----- 42

Figure 2.1: The set up of tissue grinding materials for RNA extraction kept frozen in dry ice-64

Figure 2.2: An Agilent RNA₆₀₀₀ nano chip inside a chip priming station-----67

Figure 2.3: A step-by-step sequence of sample preparation and analysis for qRT-PCR----- 73

Figure 3.1: Representative electropherogram summary of the ladder marker supplied by Agilent Technologies RNA₆₀₀₀ nano chip. Height threshold [FU] and ladder peaks [nt]. Adjacent gel output represents ladder peak markers. Measured RNA concentration = 150 ng/μl----- 77

Figure 3.2: Representative electropherogram summary of a human RNA extraction. Height threshold [FU] and ladder peaks [nt]. Adjacent gel output represents ladder peak markers. Measured RNA concentration = 77 ng/μl; rRNA Ratio [28s/18s] = 2.3 and RNA Integrity Number (RIN) = 7.1-----78

Figure 3.3: Representative gel output of a human RNA extraction whereby samples were unsuitable for further mRNA analysis. Lanes 1, 3, 4, 5, 6, 8, 9, 10 and 11 were excluded in the study. Ladder markers are represented on the y-axis, whilst the x-axis represents individual extracted human RNA sample----- 79

Figure 3.4: Representative standard curve for NFκβ in RNA extracted from women with and without endometriosis, normalized against 18S. y-axis represents the cycle threshold, whilst the x-axis represents the concentration of extracted human RNA sample-----80

Figure 4.1: Representative electropherogram summary of a baboon endometriotic RNA extraction. Height threshold [FU] and ladder peaks [nt]. Adjacent gel output represents ladder peak markers. Measured RNA concentration = 234 ng/μl; rRNA Ratio [28s/18s] = 0.7 and RNA Integrity Number (RIN) = 6.0. Refer to Figure 3.1 for a summary of the ladder marker supplied by Agilent Technologies----- 84

Figure 4.2: Representative gel output of a baboon RNA extraction whereby samples were unsuitable for further mRNA analysis. Lanes 1-10 and 12 were excluded in the study. As the RIN and quality was compromised. Ladder markers are represented on the y-axis, whilst the x-axis represents an individual baboon RNA sample from lyophilised tissues ----- 85

Figure 4.3: Representative standard curve for NFκβ in RNA extracted from baboons with endometriosis, normalized against 18S. y-axis represents the cycle threshold, whilst the x-axis represents the concentration of extracted human RNA sample-----	86
Figure 5.1: Immunohistochemical staining of baboon endometrial sections with IKKβ -----	90
Figure 5.2: Immunohistochemical staining of baboon endometrial sections with Iκβα -----	91
Figure 5.3: Immunohistochemical staining of baboon endometrial sections with NFκβ -----	92
Figure 5.4: Immunohistochemical staining of baboon endometrial sections with Ubiquitin --	94
Figure 5.5: Immunohistochemical staining of baboon endometrial sections with TNFα -----	96
Figure 5.6: Immunohistochemical staining of baboon endometrial sections with Proteasome -----	97
Figure 5.7: Immunohistochemical staining of baboon endometrial sections with IKKα -----	99
Figure 6.1: Immunohistochemical staining of baboon endometrial sections with Ubiquitin -----	106
Figure 6.2: Immunohistochemical staining of baboon endometrial sections with TNF-α ---	107
Figure 6.3: Immunohistochemical staining of baboon endometrial sections with IKKβ -----	108
Figure 6.4: Immunohistochemical staining of baboon endometrial sections with NFκβ -----	109
Figure 6.5: Immunohistochemical staining of baboon endometrial sections with Proteasome -----	111
Figure 6.6: Immunohistochemical staining of baboon endometrial sections with Iκβα -----	113

Figure 6.7: Immunohistochemical staining of baboon endometrial sections with IKKα ----	114
Figure 7.1: Immunohistochemical staining of human endometrial sections with IKKβ -----	122
Figure 7.2: Immunohistochemical staining of human endometrial sections with IκBα -----	123
Figure 7.3: Immunohistochemical staining of human endometrial sections with NFκB -----	125
Figure 7.4: Immunohistochemical staining of human endometrial sections with IKKα -----	126
Figure 7.5: Immunohistochemical staining of human endometrial sections with Proteasome -----	128
Figure 8.1: Immunohistochemical staining of human endometrial sections with IKKβ proliferative phase-----	135
Figure 8.2: Immunohistochemical staining of human endometrial sections with IKKβ secretory phase-----	136
Figure 8.3: Immunohistochemical staining of human endometrial sections with NFκB proliferative phase-----	138
Figure 8.4: Immunohistochemical staining of human endometrial sections with NFκB secretory phase-----	139
Figure 8.5: Immunohistochemical staining of human endometrial sections with Proteasome proliferative phase-----	141
Figure 8.6: Immunohistochemical staining of human endometrial sections with Proteasome secretory phase-----	142
Figure 8.7: Immunohistochemical staining of human endometrial sections with IκBα proliferative phase-----	144

Figure 8.8: Immunohistochemical staining of human endometrial sections with I$\kappa$$\beta$$\alpha$ secretory phase-----	145
Figure 8.9: Immunohistochemical staining of human endometrial sections with IKKα proliferative phase-----	147
Figure 8.10: Immunohistochemical staining of human endometrial sections with IKKα secretory phase-----	148
Figure 9.1: (A) The classical NF κ β pathway; (B) proposed mechanism during the menstrual cycle-----	152

LIST OF TABLES

Table 2.1: Antibodies for baboon tissue immunohistochemistry-----	57
Table 2.2: Antibodies for human tissue immunohistochemistry-----	61
Table 2.3: Primers for qRT-PCR-----	71
Table 2.4: List of Reagents-----	72
Table 3.1: Human mRNA expression of transcripts within the eutopic and ectopic endometrium normalized for 18S-----	76
Table 4.1: Baboon mRNA expression of NF κ β transcript within the ectopic endometrium normalized for 18S-----	84
Table 5.1: IKK- β protein immunostaining in the endometrium-----	89
Table 5.2: I κ β α protein immunostaining in the endometrium-----	89
Table 5.3: NF κ β protein immunostaining in the endometrium-----	93

Table 5.4: Ubiquitin protein immunostaining in the endometrium-----	93
Table 5.5: TNF- α protein immunostaining in the endometrium-----	95
Table 5.6: Proteasome protein immunostaining in the endometrium-----	98
Table 5.7: IKK- α protein immunostaining in the endometrium-----	98
Table 6.1: Ubiquitin protein immunostaining in ectopic [E] and eutopic endometrium-----	104
Table 6.2: TNF- α protein immunostaining in ectopic [E] and eutopic endometrium-----	104
Table 6.3: IKK- β protein immunostaining in ectopic [E] and eutopic endometrium-----	105
Table 6.4: NF κ β protein immunostaining in ectopic [E] and eutopic endometrium-----	105
Table 6.5: Proteasome protein immunostaining in ectopic [E] and eutopic endometrium-----	110
Table 6.6: I κ B α protein immunostaining in ectopic [E] and eutopic endometrium-----	112
Table 6.7: IKK- α protein immunostaining in ectopic [E] and eutopic endometrium-----	112
Table 7.1. IKK- β protein immunostaining in the endometrium-----	121
Table 7.2. I κ B α protein immunostaining in the endometrium-----	121
Table 7.3. NF κ β protein immunostaining in the endometrium-----	124
Table 7.4. IKK- α protein immunostaining in the endometrium-----	124
Table 7.5. Proteasome protein immunostaining in the endometrium-----	127

Table 8.1: IKK- β protein immunostaining in ectopic [E] and eutopic endometrium during the proliferative phase-----	134
Table 8.2: IKK- β protein immunostaining in ectopic [E] and eutopic endometrium during the secretory phase-----	134
Table 8.3: NF κ β protein immunostaining in ectopic [E] and eutopic endometrium during the proliferative phase-----	137
Table 8.4: NF κ β protein immunostaining in ectopic [E] and eutopic endometrium during the secretory phase-----	137
Table 8.5: Proteasome protein immunostaining in eutopic [E] and ectopic endometrium during the proliferative phase-----	140
Table 8.6: Proteasome protein immunostaining in eutopic [E] and ectopic endometrium during the secretory phase-----	140
Table 8.7: I κ β α protein immunostaining in ectopic [E] and eutopic endometrium during the proliferative phase-----	143
Table 8.8: I κ β α protein immunostaining in ectopic [E] and eutopic endometrium during the secretory phase-----	143
Table 8.9: IKK- α protein immunostaining in ectopic [E] and eutopic endometrium during the proliferative phase -----	146
Table 8.10: IKK- α protein immunostaining in ectopic [E] and eutopic endometrium during the secretory phases -----	146